Biomea Fusion, Inc. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Biomea Fusion, Inc. (BMEA) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-10-29.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax · last filed 2026-03-24
- Biomea Fusion, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Biomea Fusion, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2023-03-31 was $1.00K.
- Biomea Fusion, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2022-12-31 was $12.00K.
- Biomea Fusion, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for the quarter ending 2022-09-30 was $4.00K.
- Biomea Fusion, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2023 was $1.00K, a 88.89% decline from fiscal 2022.
- Biomea Fusion, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2022 was $9.00K.
- Biomea Fusion, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, after tax for fiscal 2021 was -$10.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-10-29 | |||
| 2023-12-31 | $1.00K 10-K · filed 2026-03-24 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $1.00K 10-Q · filed 2024-07-31 | $13.00K derived: sum of 3 quarters · filed 2025-03-31 | $17.00K derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | $1.00K 10-Q · filed 2024-10-29 | $13.00K derived: sum of 2 quarters · filed 2025-03-31 | $17.00K derived: sum of 3 quarters · filed 2025-03-31 | $23.00K derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $16.00K derived: sum of 2 quarters · filed 2025-03-31 | $22.00K derived: sum of 3 quarters · filed 2025-03-31 | $9.00K 10-K · filed 2025-03-31 |
| 2022-09-30 | $4.00K 10-Q · filed 2023-10-30 | $10.00K derived: sum of 2 quarters · filed 2023-10-30 | -$3.00K 10-Q · filed 2023-10-30 | -$15.00K derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | $6.00K 10-Q · filed 2023-10-30 | -$7.00K 10-Q · filed 2023-07-31 | -$19.00K derived: sum of 3 quarters · filed 2024-03-28 | -$19.00K derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | -$13.00K 10-Q · filed 2023-10-30 | -$25.00K derived: sum of 2 quarters · filed 2024-03-28 | -$25.00K derived: sum of 3 quarters · filed 2024-03-28 | -$8.00K derived: sum of 4 quarters · filed 2024-03-28 |
| 2021-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$12.00K derived: sum of 2 quarters · filed 2024-03-28 | $5.00K derived: sum of 3 quarters · filed 2024-03-28 | -$10.00K 10-K · filed 2024-03-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $17.00K derived: sum of 2 quarters · filed 2022-11-07 | $2.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $17.00K 10-Q · filed 2022-11-07 | $2.00K 10-Q · filed 2022-08-01 | ||
| 2021-03-31 | -$15.00K 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |